Pharmafile Logo
Pharmafocus logo
Advanced Search

Amneal and Zambon Biotech enter agreement for Parkinson’s treatment

February 28, 2024
Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement

Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …

News

GSK shares positive results from phase 3 trial for gonorrhoea treatment

February 27, 2024
Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea

GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …

News

Amgen opens new biomanufacturing facility in Ohio, US

February 27, 2024
Manufacturing and Production Amgen, Biomanufacturing, Manufacturing Facility, Ohio, Pharmacy, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. This will be the latest …

News

Roche shares data from phase 3 trial of Xolair as allergy treatment

February 26, 2024
Research and Development Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy

Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed …

News

Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment

February 26, 2024
Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide

Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …

News

AbbVie and Tentarix collaborate on oncology and immunology treatments

February 23, 2024
Research and Development AbbVie, Oncology, collaboration, immunology

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of …

News

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

February 23, 2024
Research and Development Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its …

News

FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review

February 22, 2024
Medical Communications FDA, Oncology, Regeneron, bla, priority review

Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …

News

BioAscent opens new protein production facility

February 22, 2024
Manufacturing and Production BioAscent, Pharmacy, facility, protein production

BioAscent has announced that it has opened its new state-of-the-art protein production facility in an event chaired by Professor Michael …

News

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

February 21, 2024
Research and Development Cabenuva, HIV, HIV/AIDS, ViiV Healthcare, clinical trial, injectables

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …

News

Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment

February 21, 2024
Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical

Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …

News

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

February 20, 2024
Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …

News

argenx announces FDA acceptance of sBLA for Vyvgart Hytrulo for CIDP treatment

February 20, 2024
Medical Communications CIDP, FDA, Neurology, Vyvgart Hytrulo, argenx, sBLA

argenx has announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for …

News

AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment

February 19, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …

News

Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment

February 19, 2024
Medical Communications Iovance, Oncology, accelerated approval, melanoma

Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …

News

Astellas and Kelonia Therapeutics enter agreement for development of immuno-oncology therapeutics

February 16, 2024
Research and Development Astellas Pharma, Kelonia Therapeutics, Oncology, collaboration, immuno-oncology

Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered …

News

Freenome raises $254m funding for early cancer detection platform

February 16, 2024
Research and Development Diagnostics, Freenome, Oncology, cancer detection, funding

Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement …

News

Domainex opens new Biology Centre of Excellence in Cambridge, UK

February 14, 2024
Business Services Pharmacy, domainex, facility

Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, …

News

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment

February 14, 2024
Medical Communications FDA, Oncology, Onivyde, ipsen, pancreatic adenocarcinoma

Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …

News

EC approves Vertex’s Casgevy for sickle cell disease treatment

February 13, 2024
Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease

Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …

News

Latest content

Rare disease clinical trials: the urgent need for patients to be heard

May 22, 2024

Sustainability in pharma

May 22, 2024

Sanofi, Formation Bio and OpenAI enter AI collaboration

May 22, 2024

Eli Lilly shares positive results from phase 3 VIVID-1 trial of Crohn’s disease treatment

May 22, 2024

GSK shares positive results from phase 3 asthma trials

May 21, 2024